• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Aridis Pharmaceuticals Inc. (Amendment)

    2/14/22 2:09:36 PM ET
    $ARDS
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ARDS alert in real time by email
    SC 13G/A 1 ards_13gv2.htm

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    SCHEDULE 13G/A

    Under the Securities Exchange Act of 1934

     

    (Amendment No. 1)*

     

     

    Aridis Pharmaceuticals, Inc.
    (Name of Issuer)
     
    Common Stock, $0.0001 par value
    (Title of Class of Securities)
     
    040334104
    (CUSIP Number)
     
    December 31, 2021
    (Date of Event Which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    x Rule 13d-1(b)
    o Rule 13d-1(c)
    o Rule 13d-1(d)

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

     

     

    CUSIP No. 04033410413G/APage 1 of 7 Pages

     

     

     

     

    1.

     

    NAME OF REPORTING PERSONS

    Catalysis Partners, LLC

     

     

    2.

     

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (SEE INSTRUCTIONS)

    (a)     o

    (b)     o

     

     

    3.

     

    SEC USE ONLY

     

     

    4.

     

     

    CITIZENSHIP OR PLACE OF ORGANIZATION

    Delaware

     

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON
    WITH

     

    5.

     

    SOLE VOTING POWER

    0

     

     

    6.

     

    SHARED VOTING POWER

    142,838

     

     

    7.

     

    SOLE DISPOSITIVE POWER

    0

     

     

    8.

     

     

    SHARED DISPOSITIVE POWER

    142,838

     

     

    9.

     

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    142,838

     

     

    10.

     

    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

    (SEE INSTRUCTIONS)

    o

     

     

    11.

     

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    1.0% (See Note 1)

     

     

    12.

     

     

    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

    PN

     

           

    (1)Based on 14,054,036 outstanding shares of Common Stock (as defined in Item 2(d) below) as of October 31, 2021 represented on the 10-Q filed with the Securities and Exchange Commission ("SEC") on November 10, 2021.

     

     

    CUSIP No. 04033410413G/APage 2 of 7 Pages

     

     

     

    1.

     

    NAME OF REPORTING PERSONS

    Francis Capital Management, LLC

     

     

    2.

     

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (SEE INSTRUCTIONS)

    (a)     o

    (b)     o

     

     

    3.

     

    SEC USE ONLY

     

     

    4.

     

     

    CITIZENSHIP OR PLACE OF ORGANIZATION

    California

     

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON
    WITH

     

    5.

     

    SOLE VOTING POWER

    0

     

     

    6.

     

    SHARED VOTING POWER

    142,838

     

     

    7.

     

    SOLE DISPOSITIVE POWER

    0

     

     

    8.

     

     

    SHARED DISPOSITIVE POWER

    142,838

     

     

    9.

     

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    142,838

     

     

    10.

     

    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

    (SEE INSTRUCTIONS)

    o

     

     

    11.

     

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    1.0% (See Note 2)

     

     

    12.

     

     

    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

    IA, HC

     

           

    (2)See Note (1) Above.

    CUSIP No. 04033410413G/APage 3 of 7 Pages

     

     

     

    1.

     

    NAME OF REPORTING PERSONS

    John Francis

     

     

    2.

     

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (SEE INSTRUCTIONS)

    (a)     o

    (b)     o

     

     

    3.

     

    SEC USE ONLY

     

     

    4.

     

     

    CITIZENSHIP OR PLACE OF ORGANIZATION

    United States

     

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON
    WITH

     

    5.

     

    SOLE VOTING POWER

    0

     

     

    6.

     

    SHARED VOTING POWER

    142,838

     

     

    7.

     

    SOLE DISPOSITIVE POWER

    0

     

     

    8.

     

     

    SHARED DISPOSITIVE POWER

    142,838

     

     

    9.

     

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    142,838

     

     

    10.

     

    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

    (SEE INSTRUCTIONS)

    o

     

     

    11.

     

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    1.0% (See Note 3)

     

     

    12.

     

     

    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

    IN, HC

     

           

    (3) See Note (1) Above.

     

    CUSIP No. 04033410413G/APage 4 of 7 Pages

     

    AMENDMENT NO. 1 TO SCHEDULE 13G

     

    Reference is hereby made to the statement on Schedule 13G filed with the Securities and Exchange Commission by the Reporting Persons with respect to the Common Stock of the Issuer on April 1, 2021 (as so amended the "Schedule 13G/A"). Terms defined in the Schedule 13G are used herein as so defined.

     

    The following Items of the Schedule 13G/A are amended and restated to read in their entirety as follows:

     

     

    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b), or 240.13d-2(b) or (c), check whether the person filing is a:

     

    (e) [x] Investment Adviser registered under Section 203 of the Investment Advisers Act of 1940

    (g) [x] Parent Holding Company or control person in accordance with Rule 13d-1(b)(1)(ii)(G)

     

    Item 4.Ownership

     

    (i)Catalysis Partners, LLC

     

    (a)Amount beneficially owned: 142,838 (See Note 4)

     

    (b)Percent of class: 1.0% (See Note 5)

     

    (c)Number of shares as to which the person has:

     

    (i)Sole power to vote or to direct the vote: 0

     

    (ii)Shared power to vote or to direct the vote: 142,838 (See Note 4)

     

    (iii)Sole power to dispose or to direct the disposition of: 0

     

    (iv)Shared power to dispose or to direct the disposition of: 142,838 (See Note 4)

     

    (ii)Francis Capital Management, LLC

     

    (a)Amount beneficially owned: 142,838 (See Note 4)

     

    (b)Percent of class: 1.0% (See Note 5)

     

    (c)Number of shares as to which the person has:

     

    (i)Sole power to vote or to direct the vote: 0

     

    (ii)Shared power to vote or to direct the vote: 142,838 (See Note 4)

     

    (iii)Sole power to dispose or to direct the disposition of: 0

     

    (iv)Shared power to dispose or to direct the disposition of: 142,838 (See Note 4)

     

    (iii)John Francis

     

    (a)Amount beneficially owned: 142,838 (See Note 4)

     

    (b)Percent of class: 1.0% (See Note 5)

     

    (c)Number of shares as to which the person has:

     

    (i)Sole power to vote or to direct the vote: 0

     

    (ii)Shared power to vote or to direct the vote: 142,838 (See Note 4)

     

    (iii)Sole power to dispose or to direct the disposition of: 0

     

    (iv)Shared power to dispose or to direct the disposition of: 142,838 (See Note 4)

     

    CUSIP No. 040334104 13G/A Page 5 of 7 Pages

     

     

    Note 4:

     

    Francis Capital Management, LLC is an investment adviser that is registered under the Investment Advisers Act of 1940. Francis Capital Management, LLC, which serves as the general partner and investment manager to Catalysis Partners, LLC ("the Fund"), may be deemed to be the beneficial owner of all shares of Common Stock held by the Fund. Mr. John Francis, as Managing Member of Francis Capital Management, LLC, with the power to exercise investment and voting discretion, may be deemed to be the beneficial owner of all shares of Common Stock held by the Fund.

     

    Note 5:

     

    Based on 14,054,036 outstanding shares of Common Stock as of October 31, 2021 represented on the 10-Q filed with the SEC on November 10, 2021.

     

      

     

    Item 5.Ownership of Five Percent or Less of a Class:

     

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following [ X ].

      

    Item 6.Ownership of More Than Five Percent on Behalf of Another Person:

     

    Not Applicable

      

    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company:

     

    Not Applicable

     

    Item 8.Identification and Classification of Members of the Group:

     

    Not Applicable

     

    Item 9.Notice of Dissolution of Group:

     

    Not Applicable

     

    Item 10.Certifications:

     

    Each of the Reporting Persons makes the following certification:

     

    By signing below each Reporting Person certifies that, to the best of its knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect. After reasonable inquiry and to the best of my knowledge and belief, the undersigned certify that the information set forth in this statement is true, complete and correct.

     

     

    Date: February 14, 2022

     

     

     

    Catalysis Partners, LLC

    By: Francis Capital Management, LLC, its General Partner

    By: /s/ John Francis

    Name: John Francis

    Title: Managing Member

     

     

    Francis Capital Management, LLC

    By: /s/ John Francis

    Name: John Francis

    Title: Managing Member

     

     

    John Francis

    By: /s/ John Francis

     

     

    CUSIP No. 040334104 13G/A Page 6 of 7 Pages

     

     

    EXHIBIT A

     

    Joint Filing Agreement Pursuant to Rule 13d-1

     

    This agreement is made pursuant to Rule 13d-l(k)(1) under the Securities Exchange Act of 1934, as amended (the "Act") by and among the parties listed below, each referenced to herein as a "Joint Filer". The Joint Filers agree that a statement of beneficial ownership as required by Sections 13(g) or 13(d) of the Act and the rules thereunder may be filed on each of his, her or its behalf on Schedule 13G or Schedule 13D, as appropriate, and that said joint filing may thereafter be amended by further joint filings. The Joint Filers state that they each satisfy the requirements for making a joint filing under Rule 13d-1(k).

     

     

    Dated: February 14, 2022
         

    Catalysis Partners, LLC

    By: Francis Capital Management, LLC, its General Partner

    By: /s/ John Francis

    Name: John Francis

    Title: Managing Member

     

     

    Francis Capital Management, LLC

    By: /s/ John Francis

    Name: John Francis

    Title: Managing Member

     

     

    John Francis

    By: /s/ John Francis

     

     

     

     

    CUSIP No. 040334104 13G/A Page 7 of 7 Pages

    Get the next $ARDS alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ARDS

    DatePrice TargetRatingAnalyst
    7/20/2021$11.00 → $19.00Buy
    HC Wainwright & Co.
    More analyst ratings

    $ARDS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Aridis Pharmaceuticals Inc.

      SC 13G/A - Aridis Pharmaceuticals, Inc. (0001614067) (Subject)

      11/14/24 4:46:40 PM ET
      $ARDS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Aridis Pharmaceuticals Inc. (Amendment)

      SC 13G/A - Aridis Pharmaceuticals, Inc. (0001614067) (Subject)

      2/14/24 2:21:52 PM ET
      $ARDS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Aridis Pharmaceuticals Inc. (Amendment)

      SC 13G/A - Aridis Pharmaceuticals, Inc. (0001614067) (Subject)

      2/13/24 8:02:49 PM ET
      $ARDS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ARDS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • HC Wainwright & Co. reiterated coverage on Aridis Pharmaceuticals with a new price target

      HC Wainwright & Co. reiterated coverage of Aridis Pharmaceuticals with a rating of Buy and set a new price target of $19.00 from $11.00 previously

      7/20/21 6:08:15 AM ET
      $ARDS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Northland Securities resumed coverage on Aridis Pharmaceuticals with a new price target

      Northland Securities resumed coverage of Aridis Pharmaceuticals with a rating of Buy and set a new price target of $22.00

      2/24/21 4:13:46 AM ET
      $ARDS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Roth Capital resumed coverage on Aridis Pharmaceuticals with a new price target

      Roth Capital resumed coverage of Aridis Pharmaceuticals with a rating of Buy and set a new price target of $18.00

      1/24/21 2:54:23 PM ET
      $ARDS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ARDS
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Patzer Eric bought $50,000 worth of Common stock purchase (714,286 units at $0.07), increasing direct ownership by 419% to 884,600 units (SEC Form 4)

      4 - Aridis Pharmaceuticals, Inc. (0001614067) (Issuer)

      6/28/24 7:32:40 PM ET
      $ARDS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CEO Truong Vu bought $50,000 worth of Common stock purchase (714,286 units at $0.07), increasing direct ownership by 108% to 1,378,639 units (SEC Form 4)

      4 - Aridis Pharmaceuticals, Inc. (0001614067) (Issuer)

      6/28/24 7:29:41 PM ET
      $ARDS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ARDS
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Aridis Provides Corporate Update

      LOS GATOS, Calif., Dec. 20, 2024 (GLOBE NEWSWIRE) -- Aridis Pharmaceuticals, Inc. (OTC:ARDS) ("Aridis" or the "Company"), a biopharmaceutical company, today announced a corporate update on recent developments. Company update: The Company continues to diligently explore multiple paths to monetize its assets amidst a protracted challenging capital market and limited internal resources. During the second half of this year it has been in discussions with other pharmaceutical companies and investment firms on possible partnerships and investments in the clinical product candidates AR-301, AR-320, AR-501, and the APEX platform technology. The Company has substantially reduced its operational

      12/20/24 8:00:00 AM ET
      $ARDS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Aridis Provides Corporate Update

      LOS GATOS, Calif., June 24, 2024 (GLOBE NEWSWIRE) -- Aridis Pharmaceuticals, Inc. (OTC:ARDS) ("Aridis" or the "Company"), a biopharmaceutical company, today announced a corporate update on recent developments. The Company has been in sustained discussions with other pharmaceutical companies and investment firms on possible partnerships and investments on its clinical product candidates AR- 301, AR-320, AR-501, and the APEX platform technology. The principal goal for the discussions has been to build shareholder value by out-licensing or attracting capital investments to complete the final stages of product development. A summary of the status of the major programs is further highlight

      6/24/24 5:58:04 PM ET
      $ARDS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Aridis Pharmaceuticals Announces Third Quarter 2023 Financial Results and Business Update

      Received two grant awards from the National Institute of Allergy and Infectious Diseases, a division of the National Institutes of Health LOS GATOS, Calif., Nov. 03, 2023 (GLOBE NEWSWIRE) -- Aridis Pharmaceuticals, Inc. (OTCQB:ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies for treating life-threatening infections, today reported financial and corporate results for its third quarter ended September 30, 2023. Third Quarter Highlights Received a grant award from the National Institute of Allergy and Infectious Diseases (NIAID) division of the National Institutes of Health (NIH), in collaboration with researchers at

      11/3/23 4:15:00 PM ET
      $ARDS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ARDS
    SEC Filings

    See more
    • Aridis Pharmaceuticals Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities

      8-K - Aridis Pharmaceuticals, Inc. (0001614067) (Filer)

      6/27/24 4:15:22 PM ET
      $ARDS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Aridis Pharmaceuticals Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

      8-K - Aridis Pharmaceuticals, Inc. (0001614067) (Filer)

      1/16/24 6:05:19 AM ET
      $ARDS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form DEFA14A filed by Aridis Pharmaceuticals Inc.

      DEFA14A - Aridis Pharmaceuticals, Inc. (0001614067) (Filer)

      12/18/23 9:43:08 AM ET
      $ARDS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ARDS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Director Hamilton John F

      4 - Aridis Pharmaceuticals, Inc. (0001614067) (Issuer)

      6/28/24 8:36:10 PM ET
      $ARDS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Windham-Bannister Susan Richards

      4 - Aridis Pharmaceuticals, Inc. (0001614067) (Issuer)

      6/28/24 8:36:12 PM ET
      $ARDS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Chief Medical Officer Jafri Hasan

      4 - Aridis Pharmaceuticals, Inc. (0001614067) (Issuer)

      6/28/24 7:46:52 PM ET
      $ARDS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ARDS
    Financials

    Live finance-specific insights

    See more
    • Reviva Pharmaceuticals Holdings, Inc. and Aridis Pharmaceuticals, Inc. Interviews to Air on the RedChip Money Report(R) on Bloomberg TV

      ORLANDO, FL / ACCESSWIRE / September 22, 2023 / RedChip Companies will air interviews with Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) and Aridis Pharmaceuticals, Inc. (OTC:ARDS) on The RedChip Money Report®, a sponsored program on Bloomberg TV, this Saturday, September 23, at 7 p.m. Eastern Time (ET). Bloomberg TV is available in an estimated 73 million homes across the U.S.Access the interviews in their entirety at:Reviva Pharmaceuticals: https://www.redchip.com/assets/access/rvph_accessAridis Pharmaceuticals: https://www.redchip.com/assets/access/ards_accessAbout The RedChip Money Report®The RedChip Money Report® is produced by RedChip Companies Inc., an international Investor Rel

      9/22/23 1:30:00 PM ET
      $ARDS
      $RVPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Aridis Pharmaceuticals, Inc., Genetic Technologies Limited, and American Resources Corporation Interviews to Air on the RedChip Money Report® on Bloomberg TV

      ORLANDO, FL / ACCESSWIRE / September 15, 2023 / RedChip Companies will air interviews with Aridis Pharmaceuticals, Inc. (OTC:ARDS), Genetic Technologies Limited ((ASX:GTG, NASDAQ:GENE), and American Resources Corporation (NASDAQ:AREC) on The RedChip Money Report®, a sponsored program on Bloomberg TV, this Saturday, September 16, at 7 p.m. Eastern Time (ET). Bloomberg TV is available in an estimated 73 million homes across the U.S.Access the interviews in their entirety at:Aridis Pharmaceuticals: https://www.redchip.com/assets/access/ards_accessGenetic Technologies: https://www.redchip.com/assets/access/gene_accessAmerican Resources: https://www.redchip.com/assets/access/arec_accessAbout The

      9/15/23 9:00:00 AM ET
      $ARDS
      $AREC
      $GENE
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Coal Mining
      Energy
    • Aridis Pharmaceuticals and Rail Vision Interviews to Air on Bloomberg TV on the RedChip Money Report(R)

      ORLANDO, FL / ACCESSWIRE / June 30, 2023 / RedChip Companies will air interviews with Aridis Pharmaceuticals, Inc. (NASDAQ:ARDS) and Rail Vision Ltd. (NASDAQ:RVSN) on The RedChip Money Report® on Bloomberg TV, this Saturday, July 1, at 7 p.m. Eastern Time (ET). Bloomberg TV is available in an estimated 73 million homes across the U.S.Access the interviews in their entirety at:Aridis Pharmaceuticals (NASDAQ:ARDS): https://www.aridispharmainfo.com/interview_accessRail Vision (NASDAQ:RVSN): https://www.rvsninfo.com/interview_accessAbout The RedChip Money Report®The RedChip Money Report® is produced by RedChip Companies Inc., an international Investor Relations and media firm with 30 years' expe

      6/30/23 9:00:00 AM ET
      $ARDS
      $RVSN
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Railroads
      Industrials